Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58-Reference-Cited by-同舟云学术

Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

Published:2020-12-29 Issue:6 Volume:23 Page:1026-1036
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Zelniker Thomas A.¹,Morrow David A.²,Mosenzon Ofri³,Goodrich Erica L.²,Jarolim Petr⁴,Murphy Sabina A.²,Bhatt Deepak L.²,Leiter Lawrence A.⁵,McGuire Darren K.⁶,Wilding John⁷,Bode Christoph⁸,Lewis Basil S.⁹,Gause‐Nilsson Ingrid¹⁰,Langkilde Anna Maria¹⁰,Fredriksson Martin¹⁰,Raz Itamar³,Sabatine Marc S.²,Wiviott Stephen D.²

Affiliation:

1. Division of Cardiology Medical University of Vienna Vienna Austria

2. TIMI Study Group, Cardiovascular Division Brigham and Women's Hospital and Harvard Medical School Boston MA USA

3. Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine Jerusalem Israel

4. Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA

5. Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto Toronto Canada

6. Division of Cardiology University of Texas Southwestern Medical Center Dallas TX USA

7. Institute of Ageing and Chronic Disease, University of Liverpool Liverpool UK

8. Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine University of Freiburg Freiburg Germany

9. Lady Davis Carmel Medical Center and the Technion‐Israel Institute of Technology Haifa Israel

10. BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

Funder

Deutsche Forschungsgemeinschaft

Bristol-Myers Squibb

AstraZeneca

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2073

Reference39 articles.

1. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

2. DECLARE‐TIMI 58: Participants’ baseline characteristics

3. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

4. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electronic Health Record Alert With Heart Failure Risk and Sodium Glucose Cotransporter 2 Inhibitor Prescriptions in Diabetes: A Randomized Clinical Trial;Journal of Diabetes Science and Technology;2024-09-10

2. Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation;Journal of the American College of Cardiology;2024-09

3. Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction;European Heart Journal;2024-05-28

4. Your Heart Function Has Normalized—What Next After TRED-HF?;Current Heart Failure Reports;2023-11-24

5. Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial;Journal of Diabetes & Metabolic Disorders;2023-09-22